R. Norris

Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men—a randomized, placebo-controlled study

D. Cooper, J. Kovacic, M. Feneley, 2006, AIDS.

No significant effect of uridine or pravastatin treatment for HIV lipoatrophy in men who have ceased thymidine analogue nucleoside reverse transcriptase inhibitor therapy: a randomized trial *

H. Wand, A. Calmy, C. Delhumeau, 2010, HIV medicine.

Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: a cross-sectional study.

B. Hirschel, D. Cooper, A. Calmy, 2009, The Journal of infectious diseases.

A Phase I study to explore the activity and safety of SCH532706, a small molecule chemokine receptor-5 antagonist in HIV type-1-infected patients

D. Cooper, S. Emery, K. Williams, 2009, Antiviral therapy.

ICON 2020—International Scientific Tendinopathy Symposium Consensus: A Systematic Review of Outcome Measures Reported in Clinical Trials of Achilles Tendinopathy

B. Vicenzino, P. Malliaras, D. Morrissey, 2021, Sports Medicine.

2021 update to HIV-TRePS: a highly flexible and accurate system for the prediction of treatment response from incomplete baseline information in different healthcare settings.

B. Gazzard, R. Kaiser, B. Larder, 2021, The Journal of antimicrobial chemotherapy.

2018 update to the HIV-TRePS system: the development of new computational models to predict HIV treatment outcomes, with or without a genotype, with enhanced usability for low-income settings

Dechao Wang, Shanmugam Saravanan, John Baxter, 2018, The Journal of antimicrobial chemotherapy.

CCR5-Δ32 genotype does not improve predictive value of IL28B polymorphisms for treatment response in chronic HCV infection

D. Booth, T. Berg, G. Ahlenstiel, 2013, Genes and Immunity.